Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells

被引:43
作者
Buss, I. [1 ]
Hamacher, A. [2 ]
Sarin, N. [1 ]
Kassack, M. U. [2 ]
Kalayda, G. V. [1 ]
机构
[1] Univ Bonn, Inst Pharm, Immenburg 4, D-53121 Bonn, Germany
[2] Univ Dusseldorf, Inst Pharmaceut & Med Chem, Univ Str 1, D-40225 Dusseldorf, Germany
关键词
CELLULAR ACCUMULATION; INFLUX TRANSPORTER; CAPILLARY-ELECTROPHORESIS; SACCHAROMYCES-CEREVISIAE; PLATINUM DERIVATIVES; BINDING BEHAVIOR; HUMAN OVARIAN; CISPLATIN; EXPRESSION; CYTOTOXICITY;
D O I
10.1039/c7mt00334j
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Oxaliplatin is a routinely used drug in the treatment of colorectal cancer. However, development of resistance is a major hurdle of the chemotherapy success. Defects in cellular accumulation represent a frequently reported feature of cells with acquired resistance to platinum drugs. Nevertheless, the mechanisms of oxaliplatin uptake and their role in oxaliplatin resistance remain poorly elucidated. The aim of this study was to investigate the relevance of copper transporter 1 (CTR1) and organic cation transporters 1-3 (OCT1-3) for oxaliplatin uptake and resistance to the drug in sensitive and oxaliplatin-resistant ileocecal colorectal adenocarcinoma cells. Co-incubation with copper(ii) sulfate, a CTR1 substrate, significantly decreased oxaliplatin accumulation but not cytotoxicity in both cell lines. Pre- as well as co-incubation with the OCT1 inhibitor atropine led to a significant reduction in oxaliplatin accumulation in sensitive but not in resistant cells. However, oxaliplatin cytotoxicity was also decreased in the presence of atropine in both cell lines. Cimetidine, an inhibitor of OCT2, induced a significant reduction in the cellular accumulation and potency of oxaliplatin in sensitive and resistant cells. An inhibitor of OCT3, decynium-22, had no influence on oxaliplatin accumulation and cytotoxicity in either cell line. No differences in the transporter expressions were observed between the cell lines, drug-treated or not, either at the mRNA or protein levels. A fluorescent oxaliplatin derivative CFDA-oxPt co-localized with CTR1, OCT1 and OCT2 in sensitive cells, but only with CTR1 and OCT2 in the resistant cell line. Our results suggest that oxaliplatin is transported into the cell by CTR1 in both cell lines. However, contribution of CTR1-mediated uptake to resistance seems unlikely. Uptake of oxaliplatin via OCT1 appears to take place in the sensitive but not in the resistant cell line underscoring the transporter relevance for oxaliplatin resistance. OCT2 is likely to be involved in the uptake of oxaliplatin to a similar extent in both cell lines suggesting no major contribution of this transporter to resistance. In contrast, OCT3 appears to be irrelevant for oxaliplatin transport into the cell and resistance.
引用
收藏
页码:414 / 425
页数:12
相关论文
共 43 条
[11]   Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3 [J].
Hayer-Zillgen, M ;
Brüss, M ;
Bönisch, H .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 136 (06) :829-836
[12]   In vitro studies on the mechanisms of oxaliplatin resistance [J].
Hector, S ;
Bolanowska-Higdon, W ;
Zdanowicz, J ;
Hitt, S ;
Pendyala, L .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (05) :398-406
[13]   Impaired cisplatin influx in an A2780 mutant cell line - Evidence for a putative, cis-configuration-specific, platinum influx transporter [J].
Helleman, Jozien ;
Burger, Herman ;
Hamelers, Irene H. L. ;
Boersma, Antonius W. M. ;
de Kroon, Anton I. P. M. ;
Stoter, Gerrit ;
Nooter, Kees .
CANCER BIOLOGY & THERAPY, 2006, 5 (08) :943-949
[14]   The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells [J].
Holzer, AK ;
Samimi, G ;
Katano, K ;
Naerdemann, W ;
Lin, XJ ;
Safaei, R ;
Howell, SB .
MOLECULAR PHARMACOLOGY, 2004, 66 (04) :817-823
[15]   Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin [J].
Holzer, Alison K. ;
Manorek, Gerald H. ;
Howell, Stephen B. .
MOLECULAR PHARMACOLOGY, 2006, 70 (04) :1390-1394
[16]   A fluorescent oxaliplatin derivative for investigation of oxaliplatin resistance using imaging techniques [J].
Kalayda, Ganna V. ;
Kullmann, Maximilian ;
Galanski, Markus ;
Gollos, Sabrina .
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, 2017, 22 (08) :1295-1304
[17]   Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines [J].
Kitada, Noriaki ;
Takara, Kohji ;
Minegaki, Tetsuya ;
Itoh, Chihiro ;
Tsujimoto, Masayuki ;
Sakaeda, Toshiyuki ;
Yokoyama, Teruyoshi .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (04) :577-584
[18]   Determination of platinum complexes in clinical samples by a rapid flameless atomic absorption spectrometry assay [J].
Kloft, C ;
Appelius, H ;
Siegert, W ;
Schunack, W ;
Jaehde, U .
THERAPEUTIC DRUG MONITORING, 1999, 21 (06) :631-637
[19]   Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications [J].
Koepsell, Hermann ;
Lips, Katrin ;
Volk, Christopher .
PHARMACEUTICAL RESEARCH, 2007, 24 (07) :1227-1251
[20]   Comparison of the binding behavior of oxaliplatin, cisplatin and analogues to 5′-GMP in the presence of sulfur-containing molecules by means of capillary electrophoresis and electrospray mass spectrometry [J].
Küng, A ;
Strickmann, DB ;
Galanski, MS ;
Keppler, BK .
JOURNAL OF INORGANIC BIOCHEMISTRY, 2001, 86 (04) :691-698